文献速递乳腺癌

阿帕替尼联合剂量密集紫杉醇卡铂新辅助治疗局部晚期三阴性乳腺癌的疗效与安全性

[Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该单中心单臂前瞻性Ⅱ期研究纳入17例Ⅱ~Ⅲ期三阴性乳腺癌患者,接受阿帕替尼联合剂量密集紫杉醇和卡铂新辅助治疗。16例可评估患者客观缓解率87.5%,疾病控制率100%,12例手术患者中8例(66.7%)达病理完全缓解,Ⅲ~Ⅳ级不良反应可控。

要点

  • 阿帕替尼联合剂量密集紫杉醇卡铂新辅助治疗局部晚期TNBC客观缓解率达87.5%。
  • 完成手术的12例中8例(66.7%)达到病理完全缓解。
  • Ⅲ~Ⅳ级不良反应以粒细胞和血小板下降为主,整体可控。

核心结论

  • 阿帕替尼联合紫杉醇和卡铂密集方案新辅助治疗局部晚期TNBC近期疗效较好,不良反应可控,未发生严重不良反应。

研究设计与样本

  • 单中心、单臂、前瞻性Ⅱ期临床研究,2018年9月至2019年9月纳入17例Ⅱ~Ⅲ期TNBC患者。
  • 治疗方案为阿帕替尼250 mg每日1次,紫杉醇175 mg/m²第1天,卡铂按AUC=4第2天,每14天为1个周期。

主要发现

  • 16例纳入统计分析,完成阿帕替尼中位5个周期、化疗中位6个周期。
  • 完全缓解2例,部分缓解12例,疾病稳定2例,客观缓解率87.5%,疾病控制率100%。
  • 12例完成手术,其中8例(66.7%)达病理完全缓解。
  • Ⅲ~Ⅳ级不良反应:粒细胞下降和血小板下降各3例(18.8%),贫血、疲乏、心律失常和丙氨酸氨基转移酶增高各1例。
  • 阿帕替尼中断治疗5例,永久停药3例,化疗减量1例。

临床怎么用

  • 该方案可作为局部晚期TNBC新辅助治疗的可选策略,但需关注血液学毒性及阿帕替尼中断或停药风险。

局限性

  • 单中心、单臂、样本量小(17例),缺乏对照组,结论需更大规模随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the short-term efficacy and safety of apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple-negative breast cancer (TNBC) patients. Methods: From September 2018 to September 2019, 17 stage Ⅱ/Ⅲ TNBC patients were enrolled in this single arm, single center prospective phase Ⅱ study. They received neoadjuvant treatment of apatinib 250 mg per day, paclitaxel 175 mg/m(2) on 1(st) day and a dose of carboplatin according to the area under curve (AUC)=4 on 2(nd) day, every 14 days as a cycle. Results: By January 2020, 16 cases completed 4-7 cycles of apatinib treatment and 4-8 cycles of chemotherapy. The median cycles of apatinib treatment and chemotherapy were 5 cycles and 6 cycles, respectively. Two cases achieved complete responses (CR), 12 achieved partial responses (PR), 2 achieved stable diseases (SD) and no progressive disease was observed. The objective response rate (ORR) was 87.5%, disease control rate (DCR) was 100%. By January 2020, among 12 patients who received surgery, 8 achieved pathologic complete response (pCR, 66.7%). The grade Ⅲ/Ⅳ adverse events included: neutropenia, thrombocytopenia in 3 cases (18.8%) each, anemia, fatigue, arrhythmia and alanine aminotransferase (ALT) elevation in 1 case each. Apatinib was interrupted in 5 cases, and was discontinued in 3 cases; chemotherapy dosage was reduced in 1 case. Conclusion: Apatinib in combination with dose-dense paclitaxel and carboplatin neoadjuvant therapy are effective and well tolerated in locally advanced TNBC patients. 目的: 观察阿帕替尼联合紫杉醇和卡铂密集方案新辅助治疗三阴性乳腺癌(TNBC)的近期疗效及安全性。 方法: 采用单中心、单臂、前瞻性Ⅱ期临床研究,纳入Ⅱ~Ⅲ期TNBC患者17例。新辅助治疗方法:阿帕替尼250 mg,1次/d;紫杉醇175 mg/m(2)第1天;卡铂给药剂量按曲线下面积=4计算,第2天;每14 d为1个周期。 结果: 16例患者纳入统计分析。16例患者完成阿帕替尼治疗的中位周期数为5个,化疗的中位周期数为6个。完全缓解2例,部分缓解12例,疾病稳定2例,客观缓解率为87.5%,疾病控制为100%。12例患者完成手术治疗,其中8例(66.7%)达病理完全缓解。Ⅲ~Ⅳ级不良反应为粒细胞下降和血小板下降各3例,贫血、疲乏、心律失常和丙氨酸氨基转移酶增高各1例。阿帕替尼中断治疗5例,永久停药3例,化疗减量1例。 结论: 阿帕替尼联合紫杉醇、卡铂密集方案新辅助化疗TNBC近期疗效较好,不良反应可控,未发生严重不良反应。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ou KP, Li Q, Luo Y, et al. [Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33256310. doi:10.3760/cma.j.cn112152-20200224-00122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。